Bioavailability of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium Is Differentially Affected by Pantoprazole in Healthy Volunteers

Journal of Clinical Pharmacology

Volumn 49, Issue 10, 2009, Pages 1196-1201

  Rupprecht, Korbinian ^a   Schmidt, Christoph ^a   Raspé, Anne ^a   Schweda, Frank ^a   Shipkova, Maria ^b   Fischer, Wolfgang ^b   Bucher, Michael ^a   Kees, Frieder ^a   Faerber, Lothar ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Novartis Pharma   (Germany)

Author keywords

Drug drug interaction; High performance liquid chromatography; Mycophenolic acid; Pharmacokinetics; Proton pump inhibitor

Indexed keywords

DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PANTOPRAZOLE; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENTERIC COATED TABLET; FEMALE; HEADACHE; HEARTBURN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCIDENCE; KIDNEY BIOPSY; KIDNEY GRAFT; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SINGLE DRUG DOSE; STOMACH PAIN;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; FEMALE; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED; TIME FACTORS;

EID: 70349479420     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009344988     Document Type: Article

References (31)

1. Arns W., Breuer S., Choudhury S., et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 2005 ; 19: 199-206.
2. Staatz CE, Tett SE Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007 ; 46: 13-58.
3. Yau WP, Vathsala A., Lou HX, Zhou S., Chan E. Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients. J Clin Pharmacol. 2009 ; 49: 684-699.
4. Bullingham R., Shah J., Goldblum R., Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996 ; 41: 513-516.
5. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060-1067
6. Kato R, Ooi K, Ikura-Mori M, et al. Impairment of mycophenolate mofetil absorption by calcium polycarbophil. J Clin Pharmacol. 2002;42:1275-1280.
7. Naderer OJ, Dupuis RE, Heinzen EL, Wiwattanawongsa K., Johnson MW, Smith PC The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol. 2005 ; 45: 219-226.
8. Brown NW, Aw MM, Mieli-Vergani G., Dhawan A., Tredger JM Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit. 2002 ; 24: 598-606.
9. Pieper AK, Buhle F., Bauer S., et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant. 2004 ; 19: 2630-2633.
10. Gimenez F., Foeillet E., Bourdon O., et al. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharmacokinet. 2004 ; 43: 685-692.
11. Kuypers DR Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant. 2008 ; 13: 11-18.
12. Naito T., Mino Y., Otsuka A., et al. Influence of metal cations on plasma trough concentration of mycophenolic acid and its glucuronide in tacrolimus-treated and cyclosporine-treated kidney transplant recipients. Biol Pharm Bull. 2008 ; 31: 1292-1296.
13. Naito T., Shinno K., Maeda T., et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull. 2006 ; 29: 275-280.
14. Naesens M., Kuypers DR, Streit F., et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther. 2006 ; 80: 509-521.
15. Morii M., Ueno K., Ogawa A., et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther. 2000 ; 68: 613-616.
16. Kuriata-Kordek M., Boratynska M., Falkiewicz K., et al. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. Transplant Proc. 2003 ; 35: 2369-2371.
17. Lam S., Partovi N., Ting LS, Ensom MH Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother. 2008 ; 42: 1037-1047.
18. Troppmann C., Papalois BE, Chiou A., et al. Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. J Am Coll Surg. 1995 ; 180: 433-443.
19. Miura M., Satoh S., Inoue K., et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008 ; 30: 46-51.
20. Shi S., Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008 ; 64: 935-951.
21. Shipkova M., Niedmann PD, Armstrong VW, et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem. 1998 ; 44: 1481-1488.
22. Shipkova M., Schutz E., Armstrong VW, Niedmann PD, Oellerich M., Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem. 2000 Mar; 46: 365-372.
23. Ramakrishna NV, Vishwottam KN, Wishu S., Koteshwara M. High-performance liquid chromatography method for the quantification of pantoprazole in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 ; 822: 326-329. (Pubitemid 40994070)
24. Xie Z., Chen X., Jin F., Zhong D. Simultaneous determination of pantoprazole and its two metabolites in dog plasma by HPLC. J Chromatogr Sci. 2005 ; 43: 271-275. (Pubitemid 40937575)
25. Steinijans VW, Hauschke D. International harmonization on regulatory bioequivalence requirements. Clin Res Reg Affairs. 1993 ; 10: 203.
26. Stedman CA, Barclay ML Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000 ; 14: 963-978.
27. Lidgate D., Brandl M., Holper M., Abubakari A., Wu X. Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil. Drug Dev Ind Pharm. 2002 ; 28: 1275-1283.
28. Saathoff N., Lode H., Neider K., Depperman KM, Borner K., Koeppe P. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother. 1992 ; 36: 796-800.
29. Ramdani A., Mignon M., Samoyeau R. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. Gastroenterol Clin Biol. 2002 ; 26: 355-359.
30. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther. 2006 ; 44: 297-302.
31. Furuta T., Shirai N., Sugimoto M., Nakamura A., Hishida A., Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005 ; 20: 153-167.